Delving into the Latest Updates on Talaporfin Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aptocine, Leserfin, Litx

+ [14]

Target-

Action-

Mechanism

Photosensitizers

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [1]

Active Indication

Esophageal CarcinomaBrain CancerLung Cancer

Inactive Indication

Breast CancerCardiovascular DiseasesChoroidal Neovascularization+ [17]

Originator Organization

Meiji Seika Pharma Co., Ltd.

Active Organization

Meiji Seika Pharma Co., Ltd.

Inactive Organization

Light Sciences Oncology, Inc.Light Sciences, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (16 Oct 2003),

Lung Cancer

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC38H41N5Na4O9

InChIKeyDSZWCAQEOJGGCM-LBARBQQXSA-N

CAS Registry220201-34-3

View All Structures (2)

Our extensive basic research on photodynamic therapy (PDT) application in models of intracranial malignant astrocytoma led to its clinical application for intracranial malignant astrocytoma in Japan. Having considered the safety and effectiveness of this pathology, we initiate a first-in-human clinical study of PDT for spinal cord malignant astrocytoma. This study has an open-label, single-arm design. The initial follow-up period is 12 months, at the end of which we will quantify survival after PDT for spinal cord malignant astrocytoma as primary objective. The secondary objective is to quantify the overall progression-free survival of treated patients and the percentage of patients surviving 6 months after PDT without recurrence. Twenty patients suffering from spinal cord malignant astrocytoma will be recruited. In particular, 10 of those should be newly diagnosed World Health Organization grade 4. After obtaining consent, each patient will receive a single intravenous injection of talaporfin sodium (40 mg/m2) 1 day before tumor resection. One day after completing tumor removal, the residual lesion and/or resection cavity will be irradiated using a 664-nm semiconductor laser with a radiation power density of 150 mW/cm2 and a radiation energy density of 27 J/cm2. The procedure will be performed 22–26 hours after talaporfin sodium administration. This study protocol has been reviewed and approved by the Certified Committee in the Japanese Ministry of Health, Labor, and Welfare University Hospital Medical Information Network Clinical Trials Registry (Japan Registry of Clinical Trials number, jRCT2021220040).

21 Oct 2024·ACS Applied Bio Materials

Water-Soluble Rotaxane-Type Porphyrin Dyes as a Highly Membrane-Permeable and Durable Photosensitizer Suitable for Photodynamic Therapy

Article

Author: Iwamura, Munetaka ; Chiba, Junya ; Ohishi, Yuki ; Yamashita, Juri ; Nozaki, Koichi ; Zhou, Yue ; Ichikawa, Taiki ; Yokoyama, Satoru ; Inouye, Masahiko

Porphyrins have emerged as highly effective photosensitizers in the field of photodynamic therapy (PDT) because of their high singlet oxygen generation efficiency. However, most porphyrin derivatives do not have adequate water solubility and cell membrane permeability suitable for use in PDT. In addition, they frequently suffer from low durability under photoirradiation. Here, we propose rotaxane-type photosensitizers, in which a porphyrin axle is irreversibly encapsulated within cyclodextrins (CDs), to overcome the drawbacks of porphyrins for PDT. The rotaxane-type photosensitizers were synthesized in high yields by employing a cooperative capture strategy. The CD derivatives worked as a transparent shell to impart a porphyrin axle not only with water solubility but also with photostability. These rotaxanes showed higher cell membrane permeability and photoinduced cytotoxic abilities than talaporfin sodium, presently used as a clinical photosensitizer. The rotaxane-based photosensitizer could have potential for being ideal PDT drugs.

01 Oct 2024·World Neurosurgery

The Safety of Intraoperative Photodynamic Diagnosis Using 5-Aminolevulinic Acid Combined with Talaporfin Sodium Photodynamic Therapy in Recurrent High-Grade Glioma

Article

Author: Miki, Shunichiro ; Matsuda, Masahide ; Kohzuki, Hidehiro ; Tsurubuchi, Takao ; Ishikawa, Eiichi ; Sugii, Narushi ; Zaboronok, Alexander

BACKGROUNDIntraoperative photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) is a widely adopted technique to enhance the extent of resection during high-grade glioma (HGG) surgery. Recent updates to the package insert for 5-ALA in Japan now allow its use in combination with drugs that may induce photosensitivity, such as talaporfin sodium (TS). TS is employed in intraoperative photodynamic therapy (PDT) and has been shown to improve overall survival. The combination of 5-ALA with TS is expected to offer further benefits. However, the safety of this combination had not been established. This study reports on the safety of 5-ALA-PDD with TS-PDT in the treatment of recurrent HGG.METHODS7 patients with recurrent HGG underwent tumor resection using a combination of 5-ALA-PDD and TS-PDT. The incidence of photosensitivity as an adverse effect associated with 5-ALA and TS was evaluated as described in the package insert. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.RESULTSTumor-specific fluorescence intensity was strong in 4 cases and weak in 3. Photosensitivity occurred in only 1 patient (14.3%). Three patients exhibited CTCAE grade 1 or 2 abnormal liver function, and 1 patient experienced CTCAE grade 1 γ-GTP elevation. All abnormalities improved during follow-up.CONCLUSIONSThe combined use of 5-ALA-PDD and TS-PDT for HGG surgery did not increase the risk of serious adverse events in our study. Further investigations with a larger number of cases are needed for a more accurate assessment of its safety and efficacy.

100 Deals associated with Talaporfin Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01985	Talaporfin Sodium	L01	DB11812

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Esophageal Carcinoma	Japan	Meiji Seika Pharma Co., Ltd.	20 May 2015
Brain Cancer	Japan	Meiji Seika Pharma Co., Ltd.	20 Sep 2013
Lung Cancer	Japan	Meiji Seika Pharma Co., Ltd.	16 Oct 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Unresectable Hepatocellular Carcinoma	Discovery	Hong Kong	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Sweden	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	South Korea	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Malaysia	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Serbia	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Poland	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Croatia	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Philippines	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	Singapore	Light Sciences Oncology, Inc.	01 Jul 2006
Unresectable Hepatocellular Carcinoma	Discovery	India	Light Sciences Oncology, Inc.	01 Jul 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	Neoplasms	-	Talaporfin PDT	gmujjkkuxb(ayweuwfqdd) = axbmrsnlgd fjxddlxzyv (aoxsenuatu ) View more	-	13 Oct 2024
				Talaporfin (STING knockout cells)	gmujjkkuxb(ayweuwfqdd) = bjvnlvxxvm fjxddlxzyv (aoxsenuatu ) View more
P11.10.B (EANO2023)	Not Applicable	Glioblastoma IDH mutant \| MGMT promotor methylation	145	PDT with Talaporfin Sodium	xoewitdasv(xmiqsudkpz) = 1 case in PDT group qvguhotinx (oscyvmscyr ) View more	Positive	08 Sep 2023
				Talaporfin sodium (Non-PDT Group)
SURG-27 (SNO2022)	Not Applicable	Recurrent Glioblastoma	-	Talaporfin sodium mediated photodynamic therapy (PDT)	oxtdgeqeit(ckswptkyfd) = no case did treatment-related severe adverse effects gmcqapurqy (dlqsbsuble )	Positive	14 Nov 2022
				Talaporfin sodium (Maximal resection alone)
UEGW2019	Not Applicable	Esophageal Carcinoma	-	Talaporfin sodium	fqqtelaoak(rkyfshwjkq) = atoejioixo qjrmgiqywc (zaxrfzjplj )	-	01 Oct 2019
ACTR-39 (SNO2016)	Phase 2	Glioblastoma	-	PDT with Talaporfin sodium and semiconductor laser	oewprpbzvs(lnsubsbjjn) = wktmrtehxy uuhzzajlms (wklhvqahkp ) View more	Positive	07 Nov 2016
				Talaporfin sodium (Surgical resection)	(zimcvvgsvf) = sixzjtcdgc vynylhkifo (hgmpyjytox ) View more
NCT00440310 (CTgov)	Phase 3	Liver metastases \| Colorectal Cancer \| Local Neoplasm Recurrence	483	Interstitial light emitting diodes+leucovorin+irrinotecan+oxaliplatin+fluorouracil+Talaporfin sodium (Litx + Chemotherapy)	(pgokvgkjhk) = jyzfuvhgem puftscefan (uylsxqimce, iiohlqrhyp - ovvuikqwth) View more	-	25 Aug 2015
				leucovorin+irrinotecan+oxaliplatin+fluorouracil (Chemotherapy Alone)	(pgokvgkjhk) = bukjcnbgru puftscefan (uylsxqimce, ywjuedvmmf - wpynbifwcs) View more
JPRN-UMIN000003970 (ASCO_GI2012)	Phase 1	Oesophageal squamous cell carcinoma recurrent \| Esophageal Carcinoma	9	Talaporfin sodium-based PDT	(gobvawktrz) = uclehyxoyx dumzqelrxw (bumfllvzqa )	-	01 Feb 2012
ASCO2006	Not Applicable	Lung Cancer	204	Laserphyrin	(wtixvmihfn) = rhlhsrybxj kyauzsheag (mpgweelfql )	-	20 Jun 2006
ASCO2005	Phase 2	Colorectal Liver Metastases	10	Talaporfin sodium + intratumoral placement of LEDs	njzragodfv(juofcplbma) = kfdbkxbksl todbteueml (zvmnkaphmw )	-	01 Jun 2005